- Home
- CLLS vs GRX Comparison
CLLS vs GRX Comparison
Compare CLLS & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- GRX
- Stock Information
- Founded
- CLLS 1999
- GRX 2007
- Country
- CLLS France
- GRX United States
- Employees
- CLLS N/A
- GRX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- GRX Finance/Investors Services
- Sector
- CLLS Health Care
- GRX Finance
- Exchange
- CLLS Nasdaq
- GRX Nasdaq
- Market Cap
- CLLS 144.4M
- GRX 154.8M
- IPO Year
- CLLS 2007
- GRX N/A
- Fundamental
- Price
- CLLS $1.53
- GRX $9.62
- Analyst Decision
- CLLS Buy
- GRX
- Analyst Count
- CLLS 3
- GRX 0
- Target Price
- CLLS $7.00
- GRX N/A
- AVG Volume (30 Days)
- CLLS 84.6K
- GRX 39.7K
- Earning Date
- CLLS 05-27-2025
- GRX 01-01-0001
- Dividend Yield
- CLLS N/A
- GRX 5.98%
- EPS Growth
- CLLS N/A
- GRX N/A
- EPS
- CLLS N/A
- GRX 0.26
- Revenue
- CLLS $49,217,000.00
- GRX N/A
- Revenue This Year
- CLLS $48.52
- GRX N/A
- Revenue Next Year
- CLLS $5.17
- GRX N/A
- P/E Ratio
- CLLS N/A
- GRX $38.50
- Revenue Growth
- CLLS 435.38
- GRX N/A
- 52 Week Low
- CLLS $1.10
- GRX $7.73
- 52 Week High
- CLLS $3.32
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- CLLS 56.17
- GRX 48.34
- Support Level
- CLLS $1.54
- GRX $9.60
- Resistance Level
- CLLS $1.65
- GRX $9.91
- Average True Range (ATR)
- CLLS 0.08
- GRX 0.16
- MACD
- CLLS -0.00
- GRX 0.03
- Stochastic Oscillator
- CLLS 58.62
- GRX 62.34
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.